What is PT-141?
An introduction to PT-141 (bremelanotide/Vyleesi), the FDA-approved treatment for HSDD.
Last updated: January 19, 2026
What is PT-141?
PT-141 (bremelanotide, brand name Vyleesi) is an FDA-approved medication for treating low sexual desire (HSDD) in premenopausal women.
Key Facts
| Fact | Detail |
|---|---|
| FDA Approved | Yes (2019) |
| Brand Name | Vyleesi |
| Indication | HSDD in premenopausal women |
| Administration | Self-injection, as needed |
How Does It Work?
PT-141 activates melanocortin-4 receptors in the brain, affecting neural pathways involved in sexual response. Unlike other treatments, it works on desire rather than physical arousal.
Who Is It For?
Vyleesi is approved for premenopausal women with:
- Low sexual desire that causes distress
- Hypoactive Sexual Desire Disorder (HSDD)
It is not approved for:
- Men
- Postmenopausal women
- General sexual enhancement
Common Side Effects
- Nausea (40% of users)
- Flushing
- Headache
- Injection site reactions
Important Notes
- Used on-demand (not daily)
- Maximum 8 uses per month recommended
- Works through the brain, not blood flow
- Requires prescription
This guide is for educational purposes only. PT-141 (Vyleesi) requires a prescription.
Related Content
CJC-1295
Hormonal · moderate evidence
Follistatin
Hormonal · moderate evidence
GHRP-2
Hormonal · moderate evidence
What is PT-141?
An introduction to PT-141 (bremelanotide/Vyleesi), the FDA-a...
PT-141 vs Kisspeptin
View side-by-side analysis
PT-141 vs Melanotan II
View side-by-side analysis
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. No spam, just evidence.
No spam. Unsubscribe anytime.
Disclaimer: This educational guide does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.